Clinical Trial Update: Safety of Sublingual dmLT for ETEC [Phase 1]

View source ↗

Summary

This Phase 1 trial update provides safety data on sublingual dmLT for enterotoxigenic Escherichia coli (ETEC)–related gastroenteritis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enterotoxigenic Escherichia Coli Infection
• Gastroenteritis

Drugs mentioned

• Sublingual dmLT (double-mutant heat-labile toxin (dmLT))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Gastroenteritis Escherichia Coli | Phase 1 | Status: COMPLETED